Abby Hardy, Author at BioTuesdays

Developments

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to acquire JT Pharmaceuticals’ kappa opioid agonist peptide, JT-09, for use in combination with Titan’s ProNeura long-term, continuous drug delivery technology, for...

October 28, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Prevail Therapeutics’ (NASDAQ:PRVL) PR001 received FDA fast track designation for the treatment of neuronopathic Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the...

October 27, 2020

Developments

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Taysha Gene Therapies (NASDAQ:TSHA) received FDA rare pediatric and orphan drug designations for TSHA-104 for the treatment of SURF1-associated Leigh syndrome. Leigh syndrome is a severe neurological disorder that...

October 27, 2020

Executive Moves

Fibrocor names William Fanslow as SVP drug development

William Fanslow Closely-held Fibrocor Therapeutics appointed industry veteran, William Fanslow Ph.D., as SVP of drug development. Dr. Fanslow has more than 20 years of experience in drug development, including both...

October 26, 2020

Developments

Imagin Medical reports agenda for KOL virtual investor event on Oct. 29

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) reported the agenda for its KOL virtual investor event taking place on Oct. 29 at 12:00 pm ET. Presenters include Jim Hutchens, Imagin’s...

October 26, 2020

Developments

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Hepion Pharmaceuticals (NASDAQ:HEPA) will present virtually at the Roth Capital “therapeutic approaches for COVID-19” event taking place on Oct. 28 from 9:00 am to 1:20 pm ET; and at the B. Riley Securities...

October 26, 2020

Developments

Titan Pharma in debt settlement pact with Molteni and Horizon

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio and Horizon Credit. The debt was secured with a lien on all assets...

October 26, 2020

Developments

Kezar KZR-616 gets FDA orphan drug designations for two autoimmune disease

Kezar Life Sciences’ (NASDAQ:KZR) KZR-616 received FDA orphan drug designation for the treatment of polymyositis and dermatomyositis, autoimmune inflammatory myopathies with marked morbidity and mortality. KZR-616 is a...

October 23, 2020

Developments

PhaseBio discontinues Phase 2 COVID-19 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) discontinued its Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of vasoactive intestinal peptide...

October 23, 2020

Executive Moves

Perimeter Medical Imaging AI names Jeremy Sobotta as CEO; Tom Boon as COO

Perimeter Medical Imaging AI (TSXV:PINK; FSE:4PC) appointed Jeremy Sobotta as its new CEO and Tom Boon as its new COO, effective immediately. Mr. Sobotta was most recently Perimeter’s CFO and replaces Tom Boon as CEO...

October 22, 2020

Author - Abby Hardy

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Fibrocor names William Fanslow as SVP drug development

Imagin Medical reports agenda for KOL virtual investor event on Oct. 29

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Titan Pharma in debt settlement pact with Molteni and Horizon

Kezar KZR-616 gets FDA orphan drug designations for two autoimmune disease

PhaseBio discontinues Phase 2 COVID-19 trial

Perimeter Medical Imaging AI names Jeremy Sobotta as CEO; Tom Boon as COO

General

More